Target intelligence / Profile preview

MicroRNA-98 (miR-98) (miR-98)

Target
miR-98
Molecular classification
Non-coding RNA, MicroRNA, let-7 family
01

Overview

MicroRNA-98 (miR-98) is a small, non-coding RNA molecule and a prominent member of the let-7 microRNA family, located on the X chromosome (Xp11.22). It plays a vital role in post-transcriptional gene regulation by binding to the 3' UTR of various target mRNAs, thereby controlling the expression of genes involved in cell growth, apoptosis, and metastasis [1, 3]. In the context of disease, miR-98 is most extensively studied in oncology, where it primarily acts as a tumor suppressor by targeting oncogenic drivers such as HMGA2, RAS, and MYC; however, its role can be context-dependent, sometimes acting as an oncomir in specific malignancies [2, 13]. Beyond cancer, miR-98 is implicated in regulating inflammatory cytokines and has been associated with neurodegenerative conditions and cardiovascular stability [9]. From a therapeutic perspective, miR-98 is being explored both as a diagnostic biomarker and a druggable target. Current therapeutic strategies focus on using miR-98 mimics to restore expression in downregulated cancers or inhibitors (antagomirs) to silence its activity when it promotes disease, though these approaches remain largely in the preclinical and early developmental stages due to challenges in targeted delivery and potential off-target effects [10, 15].

Other names
MIR98hsa-miR-98-5phsa-miR-98-3pMicroRNA 98MIRN98
02

Mechanism of action

MicroRNA-98 functions by binding to the 3' untranslated region (3' UTR) of target messenger RNAs (mRNAs) through sequence complementarity, which leads to mRNA degradation or translational inhibition of target genes such as HMGA2, RAS, and IGF1R.

03

Biological functions

Post-transcriptional gene regulationCell proliferationApoptosisCell differentiationEpithelial-mesenchymal transition (EMT)AngiogenesisInflammationMetabolism
04

Disease associations

Cancer (Hepatocellular carcinoma, lung cancer, breast cancer, gastric cancer, glioma)InflammationNeurodegenerative disease (Alzheimer's disease)Cardiovascular diseaseDiabetes
05

Safety considerations

Off-target effects due to multi-gene targetingPotential systemic toxicityInnate immune response activationDelivery vehicle-associated toxicity (e.g., lipid nanoparticles)
06

Interacting drugs

miR-98 mimics (agomirs)

1 more in the full profile.

07

Biomarkers

Tissue miR-98 expression levelsCirculating miR-98 (serum/plasma/exosomal)

Beyond the preview

Go deeper on MicroRNA-98 (miR-98) (miR-98).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA-98 (miR-98) (miR-98).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call